The objective of the phase I/IIa clinical trial, expected to include 21 patients, is to evaluate the safety and efficacy of AstroRx in patients. The trial is being conducted by the Department of Neurology of the Hadassah Ein-Kerem Medical Center.
AstroRx is an innovative cell-based treatment for ALS, which consists of brain supporting cells (astrocytes) designed to replace the astrocytes whose functionality was damaged in ALS patients. It is manufactured by Kadimastem from pluripotent stem cells using a unique technology developed by the company.
AstroRx has several mechanisms of action protecting damaged motor neurons simultaneously, as opposed to currently available treatments which use a single mechanism. The unique properties of AstroRx are expected to significantly slow down the progression of the disease, as demonstrated in pre-clinical trials.
Kadimastem develops regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells (hESCs) to treat neuro-degenerative diseases such as ALS, as well as diabetes.
The company focuses on transplanting healthy brain cells to support the survivability of nerve cells as cell therapy for ALS, and transplanting insulin-secreting pancreatic cells for the treatment of insulin-dependent diabetes.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes